Alzheimer’s Treatment: Acetylcholinesterase Inhibitors Show Long-Term Cognitive Benefits

French researchers have demonstrated that acetylcholinesterase inhibitors, used in the treatment of Alzheimer’s disease, are associated with a moderate, yet sustained, cognitive benefit over up to four years. The findings have prompted calls for a reevaluation of the 2018 decision to discontinue reimbursement for these medications in France.

Understanding Alzheimer’s and Acetylcholinesterase Inhibitors

Alzheimer’s disease is characterized by a decline in acetylcholine, a crucial neurotransmitter involved in communication between neurons, as well as muscle contraction and attention. Acetylcholinesterase is an enzyme that breaks down acetylcholine. Acetylcholinesterase inhibitors work by blocking this enzyme, increasing the availability of acetylcholine in the brain and temporarily improving or stabilizing cognitive symptoms like memory, attention and language.

The French Study: A Retrospective Analysis

The recent study, conducted by researchers in Paris and Lille, analyzed the cognitive evolution of 5,700 adults diagnosed with Alzheimer’s disease. The participants had been using acetylcholinesterase inhibitor treatments between August 1, 2017, and August 1, 2018. Researchers utilized the Mini-Mental State Examination (MMSE), a standard 30-point cognitive assessment tool, to monitor cognitive changes.

Key Findings: Sustained Cognitive Benefits

The results indicated a clear benefit from continued treatment. After one year, the average difference in cognitive decline between patients who continued treatment versus those who stopped was 0.97 points on the MMSE. This difference increased to 1.81 points after four years, demonstrating the long-term maintenance of cognitive benefits. Importantly, the study found no significant difference in mortality between the two groups over a five-year period.

Current Medications Available

Currently approved cholinesterase inhibitors include donepezil (Aricept), rivastigmine, and galantamine. Tacrine, an earlier acetylcholinesterase inhibitor, is no longer used due to its potential for liver toxicity.

Call for Reimbursement Review

Based on these findings, the researchers advocate for a review of the 2018 decision to delist acetylcholinesterase inhibitors from reimbursement coverage. They emphasize that, despite the study’s retrospective nature, the drugs remain safe and clinically relevant for individuals with mild to moderate Alzheimer’s disease.

Limitations and Future Directions

While the study provides compelling evidence, it’s essential to note that cholinesterase inhibitors are symptomatic treatments and do not alter the underlying disease progression. Further research is needed to explore combination therapies with other Alzheimer’s medications, such as NMDA receptor antagonists and antioxidant agents, to potentially enhance treatment efficacy.